An evaluation of ticagrelor for the treatment of sickle cell anemia
| Autor: | Eugênia Terra Granado Pina, Marilda Souza Goncalves, Sânzio Silva Santana, Elisângela Vitória Adorno, Isa Menezes Lyra, Cynara Gomes Barbosa, Ivana Paula Ribeiro Leite, Thassila Nogueira Pitanga, Jaime Ribeiro-Filho, Joelma Santana dos Santos Neres, J Ferreira, Sètondji Cocou Modeste Alexandre Yahouédéhou |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome Ticagrelor Anemia Sickle Cell 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Clinical Trials Phase II as Topic Internal medicine medicine Humans Thrombophilia cardiovascular diseases Myocardial infarction Blood Coagulation Clinical Trials Phase I as Topic Molecular Structure business.industry Hematology medicine.disease Platelet Activation Sickle cell anemia Clinical trial Treatment Outcome Clinical Trials Phase III as Topic 030220 oncology & carcinogenesis Cardiology Purinergic P2Y Receptor Antagonists Drug Monitoring business Platelet Aggregation Inhibitors 030215 immunology medicine.drug |
| Zdroj: | Expert review of hematology. 13(10) |
| ISSN: | 1747-4094 |
| Popis: | Ticagrelor is an antiplatelet agent approved for the treatment of patients with an acute coronary syndrome or a history of myocardial infarction. Considering the evidence demonstrating that ticagrelor-mediated inhibition of platelet activation and aggregation have beneficial effects in the treatment of thrombotic conditions, clinical studies have been conducted to evaluate the use of this drug for the treatment of sickle cell disease (SCD), demonstrating satisfactory tolerability and safety.Clinical investigation has characterized the pharmacokinetic and pharmacodynamical profile, as well as the efficacy and safety of ticagrelor to prevent painful vaso-occlusive crisis (painful episodes and acute chest syndrome) in SCD patients.While phase 1 and 2 clinical trials demonstrated satisfactory tolerability and safety, the conclusion of phase 3 clinical trials is crucial to prove the efficacy of ticagrelor as a therapeutic option for the treatment of SCD. Thus, it is expected that ticagrelor, especially in combination with other drugs, will improve the clinical profile and quality of life of patients with SCD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|